

NIH GUIDE

For Grants
and
Contracts

NOTICE OF MAILING CHANGE

Check here if you wish to
discontinue receiving this
publication

Check here if your address has
changed and you wish to con-
tinue receiving this publication.
Make corrections below and
mail this page to:

NIH Guide
Printing & Reproduction Branch
National Institutes of Health
Room B4BN08, Building 31
Bethesda, Maryland 20892

U.S. DEPARTMENT OF HEALTH
AND HUMAN SERVICES

OFFICIAL BUSINESS
Penalty for Private Use, \$300

The NIH Guide announces scientific
initiatives and provides policy and
administrative information to indi-
viduals and organizations who need to
be kept informed of opportunities,
requirements, and changes in extra-
mural programs administered by the
National Institutes of Health.

Vol. 19, No. 26
July 13, 1990

First Class Mail
Postages & Fees Paid
PHS/NIH/OD
Permit No. G-291

NOTICES OF AVAILABILITY (RFPs AND RFAs)

BRAIN AND TISSUE BANK FOR DEVELOPMENTAL DISORDERS (RFP) 1
National Institute of Child Health and Human Development
Index: CHILD HEALTH, HUMAN DEVELOPMENT

DCBDC SMALL RESEARCH GRANTS ON THE MOLECULAR AND CELLULAR BIOLOGY
OF METASTATIC TUMOR CELLS (RFA CA-90-17) 1
National Cancer Institute
Index: CANCER

NOTICES OF AVAILABILITY (RFPs AND RFAs)

BRAIN AND TISSUE BANK FOR DEVELOPMENTAL DISORDERS

RFP AVAILABLE: RFP NICHD-90-17

P.T. 34; K.W. 0780005, 0705010

National Institute of Child Health and Human Development

The National Institute of Child Health and Human Development (NICHD) is planning to set up a repository to collect, store, and distribute specimens from infants and children with neurodevelopmental disorders from both "unaffected" (control) individuals and individuals with developmental disorders. The biopsy and/or autopsied tissues to be included in the brain and tissue bank would encompass the following disorders: diagnosed Down's syndrome, other chromosome defects, mitochondrial encephalopathies, phenylketonuria and other aminoacidopathies, maternal PKU, Rett syndrome, leukodystrophies, lysosomal disorders, unexplained forms of mental retardation, sudden infant death syndrome (SIDS), dyslexia, autism, and other neurodevelopmental problems. Specific tissues to be collected will include the following: brain, spinal cord, cerebrospinal fluid, blood and serum, peripheral nerves, liver, kidney, pancreas, lungs, spleen, adrenal, skeletal muscles, heart, skin, thyroid, lymph nodes, and gonads. Tissues would be obtained premortem, postmortem and from abortions. These tissues will be made available to qualified investigators to support and facilitate research that will lead to an improved understanding of the etiology, pathology, pathogenesis, and clinical-pathological correlation of conditions that are associated with mental retardation, learning and behavioral deficits, and SIDS.

This announcement for a brain and tissue bank is a new solicitation. The issuance of this RFP will be on or about August 6, 1990, and proposals are due by 4:00pm (Local Time), October 15, 1990. The Institute plans to make one award from this solicitation. Those organizations desiring a copy of the above RFP may send their written request to:

Mrs. Lynn Salo
NICHD, OGC, CMS
Executive Plaza North Bldg., Rm. 515
9000 Rockville Pike
Bethesda, MD 20892

To receive a copy of the RFP, please supply this office with two self-addressed mailing labels. All responsible sources may submit a proposal which will be considered. This advertisement does not commit the Government to award a contract.

DCBDC SMALL RESEARCH GRANTS ON THE MOLECULAR AND CELLULAR BIOLOGY OF METASTATIC TUMOR CELLS

RFA AVAILABLE: CA-90-17

P.T. 34; K.W. 1002004, 1002008, 0715035

National Cancer Institute

Letter of Intent Receipt Date: September 10, 1990
Application Receipt Date: October 10, 1990

I. INTRODUCTION

The Cancer Biology Branch of the Division of Cancer Biology, Diagnosis and Centers (DCBDC) at the National Cancer Institute (NCI) invites applications for grants to study the molecular and cellular biology of metastatic tumor cells. This special initiative is designed to promote collaborations and facilitate scientific interchange between investigators, one with experience in the biology of metastasis and the other in a more basic scientific discipline such as molecular or cellular biology or biochemistry. Prospective principal investigators are encouraged to identify a research collaborator in order to prepare and submit a small grant application.

The Small Research Grants program provides limited funds (maximum of \$40,000 per year) for short-term (up to 2 years) research projects. They are non-renewable. Small grants provide an opportunity for initiating studies which may be preliminary in nature. Research investigators in relevant fields

are invited to apply for these grants in order to develop preliminary data that could form the basis of future R01 or R29 applications.

The present Request for Applications (RFA) announcement is for a single solicitation with a specified deadline (October 10, 1990) for receipt of applications. There will be up to ten awards if meritorious applications and funds are available.

II. RESEARCH GOALS AND SCOPE

The goal of this initiative is to provide funds for preliminary research projects that will form the basis of future R29 and R01 applications to investigate metastasis. The intent is to (1) foster collaborative research between investigators with basic molecular and cellular biological and biochemical research experience, and those with experience in metastasis research, and (2) increase the number of laboratories and investigators addressing issues of metastasis.

The scope of the research may encompass any aspect of molecular and cellular biology and biochemistry as they apply to metastasis biology. Applications should be for preliminary data gathering or pilot feasibility studies, and should be founded on the combined research experience of the principal investigator and his/her collaborator. The application should specifically address how the application meets the intent of the initiative, e.g., the development of a new collaboration between an investigator with basic molecular and cellular biological and biochemical research experience and one with experience in metastasis research. Furthermore, the research collaborator should address how the proposed research will relate to and integrate with other ongoing research in his/her laboratory. Either the principal investigator or the research collaborator must have demonstrated experience in metastasis research. However, the initiative is not intended for support of applicant investigators who have such experience and propose collaborating with laboratories that are also engaged in metastasis research in any significant manner. The research collaborator may collaborate with more than one principal investigator.

The principal investigator must be accountable to the recipient organization officials for the proper conduct of the project. The research collaborator must be named and time and effort listed on the budget page. The recipient organization is legally responsible and accountable to PHS for performance and financial aspects of the grant-supported activity.

Just as the initiative is intended to foster a research collaboration, the application itself should clearly be the product of in-depth discussions and input from both the research collaborator and the principal investigator.

III. MECHANISM OF SUPPORT

Support of this program will be through the National Institutes of Health (NIH) grant-in-aid. Applicants will be responsible for the planning, direction, and execution of the proposed project. Except as otherwise stated in this RFA, awards will be administered under PHS policy as stated in the Public Health Service Grants Policy statement, DHHS Publication No. (OASH) 82-50,000, revised January 1, 1987.

This RFA is a one-time solicitation. Grants made under this mechanism are non-renewable.

Approximately \$600,000 in total costs per year for two years will be committed to specifically fund applications which are submitted in response to this RFA. It is anticipated that 10 awards will be made. The total direct costs per year must not exceed \$40,000. This funding level is dependent on the receipt of a sufficient number of applications of high scientific merit. The total project period for applications submitted in response to the present RFA should be for at least one (1) year and may not exceed two (2) years. The earliest feasible start date for the initial award will be March 1, 1991. However, the award date may be delayed to as late as August 1, 1991. Although this program is provided for in the financial plans of the NCI, the award of grants pursuant to this RFA is also contingent upon the availability of funds for this purpose.

IV. INQUIRIES

Written or telephone inquiries concerning the objectives and scope of this RFA or inquiries about whether or not specific proposed research would be responsive are encouraged and should be directed to Dr. Michael R. Martin at the address below. The Program Director welcomes the opportunity to clarify any issues or questions from potential applicants.

Dr. Michael R. Martin
Program Director for Basic Cancer Biology
National Cancer Institute
Executive Plaza South, Room 630
6120 Executive Blvd.
Rockville, MD 20892
Telephone: (301) 496-7028
Fax: (310) 496-8656